Publicacións en colaboración con investigadores/as de Dana–Farber Cancer Institute (9)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Correction to: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial (Nature Communications, (2024), 15, 1, (5251), 10.1038/s41467-024-49121-3)

    Nature Communications

  4. Correction to: dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe (Nature Communications, (2024), 15, 1, (3736), 10.1038/s41467-024-47751-1)

    Nature Communications

  5. dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe

    Nature Communications, Vol. 15, Núm. 1

2000

  1. Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F regulation

    Molecular and Cellular Biology, Vol. 20, Núm. 13, pp. 4745-4753

1996

  1. Cyclin E, a redundant cyclin in breast cancer

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 93, Núm. 26, pp. 15215-15220

  2. Simian virus 40 large T antigen alters the phosphorylation state of the RB-related proteins p130 and p107

    Journal of Virology, Vol. 70, Núm. 5, pp. 2781-2788

1995

  1. Role of pRb-related proteins in simian virus 40 large-T-antigen-mediated transformation

    Molecular and Cellular Biology, Vol. 15, Núm. 10, pp. 5800-5810